BiotechTube

Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scalp Psoriasis

Conditions

Scalp Psoriasis

Trial Timeline

Oct 20, 2017 → Oct 25, 2018

NCT ID
NCT03331523

About Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo

Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03331523. Target conditions include Scalp Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03331523Phase 3Completed

Competing Products

7 competing products in Scalp Psoriasis

See all competitors
ProductCompanyStageHype Score
DSXS topical productSun PharmaceuticalPhase 2
52
PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
77
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
77
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspensionSun PharmaceuticalPhase 1
33
Secukinumab 300 mg + PlaceboNovartisPhase 3
77
Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3
72

Other Products from Glenmark Pharmaceuticals

Nitric OxidePhase 3
77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerPhase 3
77
Diclofenac Sodium gel, 1% + Voltaren® Gel + PlaceboPhase 3
77
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)Phase 3
77
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% + PlaceboPhase 3
77